Results 11 to 20 of about 1,591,431 (356)

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

New England Journal of Medicine, 2021
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the ...
J. Lopez Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E. Tessier, N. Groves, G. Dabrera, R. Myers, C. Campbell, G. Amirthalingam, Matt Edmunds, M. Zambon, K. Brown, S. Hopkins, M. Chand, M. Ramsay   +18 more
semanticscholar   +1 more source

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Nature, 2023
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients^ 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines ^ 2 , 3 .
Luis A. Rojas, Zachary M. Sethna, K. Soares, C. Olcese, N. Pang, Erin Patterson, J. Lihm, N. Ceglia, Pablo Guasp, A. Chu, Rebecca Yu, A. Chandra, T. Waters, J. Ruan, M. Amisaki, Abderezak Zebboudj, Z. Odgerel, George Payne, E. Derhovanessian, F.-J. Müller, I. Rhee, M. Yadav, Anton Dobrin, M. Sadelain, M. Łuksza, Noah Cohen, Laura A Tang, O. Basturk, M. Gönen, S. Katz, R. Do, A. Epstein, Parisa Momtaz, Wungki Park, R. Sugarman, A. Varghese, E. Won, A. Desai, Alice C. Wei, M. D'Angelica, T. Kingham, I. Mellman, T. Merghoub, J. Wolchok, U. Şahin, Ö. Türeci, B. Greenbaum, W. Jarnagin, J. Drebin, E. O’Reilly, V. Balachandran   +50 more
semanticscholar   +1 more source

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

The Lancet, 2022
Summary Background Knowing whether COVID-19 vaccine effectiveness wanes is crucial for informing vaccine policy, such as the need for and timing of booster doses.
D. Feikin, Melissa M. Higdon, L. Abu-Raddad, N. Andrews, R. Araos, Y. Goldberg, M. Groome, A. Huppert, Katherine L. O’Brien, Peter G. Smith, A. Wilder-Smith, S. Zeger, M. Deloria Knoll, M. Patel   +13 more
semanticscholar   +1 more source

Therapeutic cancer vaccines: advancements, challenges and prospects

Signal Transduction and Targeted Therapy, 2023
With the development and regulatory approval of immune checkpoint inhibitors and adoptive cell therapies, cancer immunotherapy has undergone a profound transformation over the past decades.
Ting Fan, Mingna Zhang, Jingxian Yang, Zhounan Zhu, Wanlu Cao, Chunyan Dong   +5 more
semanticscholar   +1 more source

A Comprehensive Review of mRNA Vaccines

International Journal of Molecular Sciences, 2023
mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low-cost manufacturing.
Vrinda Gote, Pradeep Kumar Bolla, Nagavendra Kommineni, Arun Butreddy, Pavan Nukala, S. Palakurthi, Wahid Khan   +6 more
semanticscholar   +1 more source

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

The Lancet, 2021
The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with
O. Wouters, Kenneth C. Shadlen, Maximilian Salcher-Konrad, A. Pollard, H. Larson, Y. Teerawattananon, M. Jit   +6 more
semanticscholar   +1 more source

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

British medical journal, 2021
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the UK variant of concern B.1.1.7), admissions to hospital, and deaths.
J. Lopez Bernal, N. Andrews, C. Gower, C. Robertson, J. Stowe, E. Tessier, R. Simmons, S. Cottrell, R. Roberts, M. O’Doherty, K. Brown, C. Cameron, D. Stockton, J. McMenamin, M. Ramsay   +14 more
semanticscholar   +1 more source

Nanomaterial Delivery Systems for mRNA Vaccines

Vaccines, 2021
The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as ...
M. Buschmann, Manuel J. Carrasco, Suman Alishetty, M. Paige, M. Alameh, D. Weissman   +5 more
semanticscholar   +1 more source

Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic.

Asian Pacific Journal of Allergy and Immunology, 2020
As the world is witnessing the epidemic of COVID-19, a disease caused by a novel coronavirus, SARS-CoV-2, emerging genetics and clinical evidences suggest a similar path to those of SARS and MERS.
E. Prompetchara, C. Ketloy, T. Palaga
semanticscholar   +1 more source

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

New England Journal of Medicine, 2022
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom.
N. Andrews, E. Tessier, J. Stowe, C. Gower, Freja C M Kirsebom, R. Simmons, E. Gallagher, S. Thelwall, N. Groves, G. Dabrera, R. Myers, C. Campbell, G. Amirthalingam, Matt Edmunds, M. Zambon, K. Brown, S. Hopkins, M. Chand, S. Ladhani, M. Ramsay, J. Lopez Bernal   +20 more
semanticscholar   +1 more source